The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma

The ubiquitin-proteasome signaling pathway is critical for cell cycle regulation and neoplastic growth. Proteasome inhibition can activate apoptotic pathways. Bortezomib, a selective proteasome inhibitor, has anti-melanoma activity. MLN2238 (ixazomib), an oral proteasome inhibitor, has improved phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Suarez, Lorena P., Kemper, Gregory M., Duggan, Megan C., Stiff, Andrew, Noel, Tiffany C., Markowitz, Joseph, Luedke, Eric A., Yildiz, Vedat O., Yu, Lianbo, Jaime-Ramirez, Alena Cristina, Karpa, Volodymyr, Zhang, Xiaoli, Carson, William E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348384/
https://www.ncbi.nlm.nih.gov/pubmed/27783987
http://dx.doi.org/10.18632/oncotarget.12791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348384/
https://www.ncbi.nlm.nih.gov/pubmed/27783987
http://dx.doi.org/10.18632/oncotarget.12791

Ejemplares similares